Decreased serum butyric acid levels correlate with increased intestinal permeability as measured by serum intestinal fatty acid binding protein (I-FABP) and bacterial lipopolysaccharide (LPS) in MS patients compared to healthy controls. The gene discussed is FABP2; the disease is myeloid sarcoma.